Tier 3 — preclinical
Berberine and rifaximin effects on small intestinal bacterial overgrowth: Study protocol for an investigator-initiated, double-arm, open-label, randomized clinical trial (BRIEF-SIBO study)
Frontiers in pharmacology
2023
14:1121435
Bibliography
- PubMed
- PMID 36873985
- PubMed Central
- PMC9974661
- Funding
- Supported by grant JKCJ202101 from the International Institute of Population Health, Peking University Health Science Center, China. The protocol states that the funder had no design role and would have no role in trial execution, analysis, interpretation or submission.
- Competing interests
- Authors declare no commercial or financial relationships that could be construed as a potential conflict of interest.
Study snapshot
| Design | Published randomized-trial protocol; not an outcome report |
|---|---|
| Model | Human participants; protocol only |
| Sample | 180 participants planned; no completed-trial outcome data in this paper |
| Intervention | Planned berberine 400 mg twice/day versus rifaximin 400 mg twice/day |
| Duration | 2 weeks of treatment; 6-week total follow-up planned |
| Endpoints | Planned primary endpoint: negative lactulose hydrogen-methane breath test; Planned secondary endpoints: abdominal symptoms and gut microbiota |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Citation network
Articles citing this research paper
Biohack Blueprint analyses that reference this study in their evidence base.
- Berberine and Gut Health: Microbiome, IBS and Infection ResearchBerberine gut-health research explained: microbiome trials, IBS-D, SIBO boundaries, H. pylori combinations, adenoma recurrence and digestive safety.Read analysis
- Berberine for SIBO: Trial Evidence, Herbal Formulas and SafetyBerberine for SIBO: audit the herbal comparison, BRIEF-SIBO protocol and conference results, methane questions, combinations and treatment limitations.Read analysis
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified
